Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	237	117	112	383	78	15
Revenue Growth (YoY)	99.16%	4.46%	-70.76%	391.03%	420.00%	79.58%
Gross Profit	237	117	112	383	78	15
Selling, General & Admin	119	117	104	72	43	25.23
Research & Development	368	340	288	257	159	78.48
Other Operating Expenses	20	0	0	0	0	0
Operating Expenses	507	457	392	329	202	103.71
Operating Income	-270	-340	-280	54	-124	-88.71
Other Expense / Income	-43	-39	-14	-1	-1	-4
Pretax Income	-227	-301	-266	55	-123	-84.71
Income Tax	4	6	1	2	0	0
Net Income	-231	-307	-267	53	-123	-84.71
Shares Outstanding (Basic)	86	74	72	69	55	44
Shares Outstanding (Diluted)	86	74	72	74	55	44
Shares Change	18.08%	2.78%	-2.70%	35.04%	25.04%	26.60%
EPS (Basic)	-3.11	-4.15	-3.71	0.76	-2.24	-1.93
EPS (Diluted)	-3.11	-4.15	-3.71	0.71	-2.24	-1.93
Free Cash Flow	-235	-330	432	-282	108	-75.39
Free Cash Flow Per Share	-2.73	-4.46	6.00	-4.07	1.97	-1.72
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-113.92%	-290.60%	-250.00%	14.10%	-158.97%	-591.39%
Profit Margin	-97.47%	-262.39%	-238.39%	13.84%	-157.69%	-564.73%
Free Cash Flow Margin	-99.16%	-282.05%	385.71%	-73.63%	138.46%	-502.58%
Effective Tax Rate	-	-	-	3.64%	-	-
EBITDA	-210	-285	-252	62	-119	-81.13
EBITDA Margin	-88.61%	-243.59%	-225.00%	16.19%	-152.56%	-540.88%
Depreciation & Amortization	17	16	14	7	4	3.58
EBIT	-227	-301	-266	55	-123	-84.71
EBIT Margin	-95.78%	-257.26%	-237.50%	14.36%	-157.69%	-564.73%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).